Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after preoperative chemoTherapy and radical surgerY: the TRINITY study.
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after preoperative chemoTherapy and radical surgerY: the TRINITY study.
Patologie
Stato
Aperto - reclutamento in corso
Codice studio
TRINITY
Codice EudraCT
2023-506662-31-00
Sponsor/Promotore
GONO Gruppo Oncologico Nord Ovest
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator